Regulatory Affairs Management
Leading regulatory affairs managers can act as a seamless extension of Sponsor regulatory teams.
Thanks to MMS and especially the team… we reset the relationship that we have with the FDA and moved our lead asset forward through to getting our clinical trial started.
MMS regulatory strategy experts provide consulting and can be assigned as the product lead or a lead for a specific submission type, if needed.
MMS Regulatory Affairs Managers are a true extension of Sponsor regulatory affairs teams. These knowledgeable, experienced resources are assigned to specific products and applications and work with Sponsor teams to execute regulatory activities and facilitate optimal progress and development.
Our Regulatory Affairs Managers are responsible to support the following:
- Communication of regulatory requirements and provision of status updates to stakeholders in the Sponsor company
- Development of Module 1 content required for global health authority interactions, including the FDA, EMA, and others
- Review of required regulatory documentation and files created by other functional lines
- Representation to and interactions with global health authorities on behalf of the Sponsor
Leads the team in the preparation and execution of large and/or complex dossiers
For more information on submissions support, see here.
Regulatory Affairs Managers and Strategists regularly create regional, Module 1 documentation and provide the Sponsor team with expert guidance on the content and format needed to support key interactions with global health authorities.
Suggested For You
perspectives
October 8th, 2024
Diversity Action Plan Guidance Part I: Implications for Sponsors
webinar
October 22nd, 2024
Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules
perspectives
September 30th, 2024
Meet the Leaders Driving MMS’s European Growth
perspectives
September 30th, 2024
The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry
perspectives
September 24th, 2024
Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry
perspectives
September 11th, 2024
From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs
webinar
September 26th, 2024
Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance
perspectives
September 4th, 2024
Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders
perspectives
August 27th, 2024
Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs
regulatory intelligence
August 27th, 2024
Recent Guidance on Diversity Action Planning
regulatory intelligence
August 26th, 2024
Oncology Programs at the FDA
regulatory intelligence
August 26th, 2024
Three Key Take Reflections on the Recent Donanemab Approval